Eledon Pharmaceuticals, Inc. (ELDN)
NASDAQ: ELDN · Real-Time Price · USD
2.600
+0.040 (1.56%)
Aug 22, 2025, 4:00 PM - Market closed

Eledon Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 20202016 - 2020
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2016 - 2020
Selling, General & Admin
19.6418.6112.6913.113.437.35
Upgrade
Research & Development
68.2651.9630.3126.6823.445.93
Upgrade
Operating Expenses
87.970.584339.7836.8713.28
Upgrade
Operating Income
-87.9-70.58-43-39.78-36.87-13.28
Upgrade
Other Non Operating Income (Expenses)
102.9834.82-73.540.460.010.08
Upgrade
EBT Excluding Unusual Items
15.07-35.75-116.54-39.32-36.86-13.2
Upgrade
Merger & Restructuring Charges
------5.18
Upgrade
Impairment of Goodwill
----48.65--
Upgrade
Other Unusual Items
------4.83
Upgrade
Pretax Income
15.07-35.75-116.54-87.97-36.86-23.22
Upgrade
Income Tax Expense
0.430.43---2.35-0.4
Upgrade
Net Income
14.64-36.18-116.54-87.97-34.51-22.81
Upgrade
Net Income to Common
14.64-36.18-116.54-87.97-34.51-22.81
Upgrade
Shares Outstanding (Basic)
69492514151
Upgrade
Shares Outstanding (Diluted)
69492514151
Upgrade
Shares Change (YoY)
108.60%97.18%72.34%-3.61%921.03%121.42%
Upgrade
EPS (Basic)
0.21-0.75-4.73-6.16-2.33-15.72
Upgrade
EPS (Diluted)
0.21-0.75-4.73-6.16-2.33-15.72
Upgrade
Free Cash Flow
-64.53-47.27-39.53-28.42-28.91-15.21
Upgrade
Free Cash Flow Per Share
-0.94-0.97-1.61-1.99-1.95-10.48
Upgrade
EBITDA
-----36.86-13.28
Upgrade
D&A For EBITDA
----0.010.01
Upgrade
EBIT
-87.9-70.58-43-39.78-36.87-13.28
Upgrade
Updated Aug 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q